<DOC>
	<DOCNO>NCT00770952</DOCNO>
	<brief_summary>The purpose study determine effect pioglitazone , daily ( QD ) , glimepiride combination therapy compare glimepiride monotherapy subject Type 2 Diabetes .</brief_summary>
	<brief_title>Efficacy Pioglitazone Glimepiride Combination Therapy Treating Subjects With Type 2 Diabetes Mellitus .</brief_title>
	<detailed_description>Tight glycemic control mandatory prevention treatment vascular complication patient suffer diabetes mellitus . After onset Type 2 Diabetes , patient usually treat diet along without different combination oral drug . One first-line drug class sulfonylurea drug preferably provide patient obese . The mode action sulfonylurea drug increase beta-cell secretion , could show lead deterioration beta-cell secretion product time , result increase proinsulin secretion . Since proinsulin independent cardiovascular risk factor , recent publication demonstrate increase risk cardiovascular event patient treat sulfonylurea drug compare treatment method . Combination therapy sulfonylurea drug glitazones show counterbalance effect deteriorate beta-cell secretion improve insulin sensitivity level proinsulin , C-peptide laboratory surrogate marker cardiovascular risk . Proving treatment diabetic patient higher dos beta cytotropic agent avoid beta-cell function preserve use pioglitazone combination low dose sulfonylurea drug , possible optimize treatment patient type 2 diabetes control efficiently sulfonylurea drug monotherapy . In study patient enrol inefficiently treat Glimepiride monotherapy . Patients either randomized combinational therapy Pioglitazone Glimepiride Glimepiride monotherapy . If possible , study medication up-titrated maximal dosage level treatment arm observe maximal comparable treatment effect . Stable effect beta-cell function observe 24 week treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 Diabetes accord American Diabetes Association Criteria . Treatment Glimepiride monotherapy ( 13 mg per day ) 3 month enter study . Glycosylated hemoglobin great 6.5 % , le 8.5 % and/ fast plasma glucose great 7 mmol/l within last 4 week . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Type 1 Diabetes mellitus . History hypersensitivity study drug drug similar chemical structure . Progressive fatal disease . History drug alcohol abuse last 5 year . More one unexplained episode severe hypoglycemia within 6 month prior enter study . A history significant cardiovascular ( New York Heart Association stage I IV ) , respiratory , gastrointestinal , hepatic ( alanine aminotransferase great 2.5 time upper limit normal reference range ) , renal ( serum creatinine great 1.8 mg/dl ; glomerular filtration rate le 40 ml/min estimate CockroftGault formula ) , neurological , psychiatric and/or hematological disease , history macular edema . Blood donation within last 30 day . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : CYP2C9 inductor CYP2C9 inhibitor rifampicin fluconazole drug use treat type 2 diabetes ( insulin , insulin analogous compound oral antidiabetic drug ) Pretreatment thiazolidinediones within last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus , Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>